Fujifilm Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organisation (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention in Boston, Massachusetts.
pAVEway™ was developed by FUJFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E. coli -based processes.
“As a CDMO we established ourselves early on as a leader in microbial process development and manufacturing,” said Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies. “Completing 100 programs and seeing many of them successfully transferred from the lab into cGMP manufacturing and subsequently to the clinic is fulfilling to everyone at Fujifilm.”
One of the differentiators of the pAVEway™ system is its ability to control protein expression by allowing expression and secretion to be coupled. It also allows for slower expression, which can result in a higher chance of folding, and to sustain accumulation for many hours with continued cell growth. The system has proven to be well suited to investigate difficult to express proteins with protein toxicity to the cells, folding and periplasmic secretion being just some of the challenges encountered and overcome with the pAVEway™ system.